Cantargia: Closing in on a Licensing Deal?

Redeye updates its view on Cantargia following a period that has brought promising trial results and the initiation of several new clinical projects. We adjust our estimates and valuation based on new timelines and an updated WACC.


Richard Ramanius

Disclosures and disclaimers

Premium Plan required to unlock

Unlock companies to access

more high quality research.